Download as pdf or txt
Download as pdf or txt
You are on page 1of 28

CURRICULUM VITAE

Dr. GERY DALA PRIMA BASO, SpPD

TTL : Makassar, 04 Oktober 1985

Alamat : Jalan Kesehatan No.3, Dok 2 Jayapura Papua


Status Pernikahan : Menikah

Pendidikan Jabatan/Pekerjaan
• Sp Ilmu Penyakit Dalam, Universitas Indonesia (2018) • Staf bagian Ilmu Penyakit Dalam RSU
• Pendidikan Dokter, Universitas Hasanuddin (2009)
Jayapura
• SMA Negeri 2, Jayapura (2003)
• SMP Kr. Kalam Kudus, Jayapura (2000) • Ketua Komite PPRA RSU Jayapura
• SD Kr. Kalam Kudus, Jayapura (1997) • Kepala Unit TB – HIV RSU Jayapura
• SD Harapan Bunda, Jakarta (1993)
HYPERTENSION IN
CHRONIC KIDNEY DISEASE

Dr. Gery Dala P. Baso, SpPD


Penyakit Dalam RSU Jayapura
FK Universitas Cenderawasih
HIPERTENSI
INTRODUCTION
Hypertension = High Blood Pressure

http://sharinginhealth.org/biology/blood_pressure
HIPERTENSI

PATHOPHYSIOLOGY
HIPERTENSI
PATHOPHYSIOLOGY
HYPERTENSION - CKD

Ku, E, et al. Hypertension in CKD: Curriculum 2019.


American Journal of Kidney
HIPERTENSI PATOFISIOLOGI

Factors – Hypertension in CKD

FM Tedla. Hypertension in Chronic Kidney Disease


Journal of Hypertension
HIPERTENSI
INTRODUCTION

Hypertension - CKD are interlinked pathophysiologic


states
• Sustained hypertension  worsening kidney function
• Progressive decline in kidney function  worsening blood pressure
(BP) control
• Clinical Trials  BP control not always affecting progression of CKD,
• Intensive BP control reduces the risk for adverse cardiovascular +
mortality in CKD

Ku, E, et al. Hypertension in CKD: Curriculum 2019.


American Journal of Kidney
HIPERTENSI

Stages of CKD – Risk & Mortality

KDIGO 2012
HIPERTENSI
CRITERIA

DEFINITIONS OF NORMAL AND ABNORMAL BP BASED ON THE


2017 AHA/ACC GUIDELINE IN PATIENTS WITH CKD

Accurate BP Measurement
• ABPM Preferred
• Clinic : 5 min Rest, calibrated cuff
device, no caffeine+exercise 30 min
prior, at least 2-3 readings

Ku, E, et al. Hypertension in CKD: Curriculum 2019.


American Journal of Kidney
HIPERTENSI
CRITERIA

ESC/ESH CLASSIFICATION OF BP
AND DEFINITIONS HYPERTENSION GRADE

2018 ESC/ECH Hypertension Guidelines


HIPERTENSI
CRITERIA

2017 AHA/ACC GUIDELINE IN PATIENTS WITH CKD


DIFFICULT TO CONTROL

Ku, E, et al. Hypertension in CKD: Curriculum 2019.


American Journal of Kidney
HIPERTENSI DIAGNOSIS
Causes of Secondary Hypertension

If & When :
• Elevated BP before puberty
• Severe/malignant HT
• Sudden worsening of BP
• Electrolyte Imbalance

• Special Workup & Analysis


•  Consult Internal
Medicine/Nephrologist
Ku, E, et al. Hypertension in CKD: Curriculum 2019.
American Journal of Kidney
TREATMENT
HIPERTENSI
INISIASI TERAPI FARMAKOLOGIS

Konsensus inaSH 2019.


HIPERTENSI
STRATEGI TATALAKSANA HIPERTENSI TANPA KOMPLIKASI

Konsensus inaSH 2019.


HIPERTENSI

JNC VIII Guideline. 2014


HIPERTENSI
TREATMENT
Lifestyle Modification
WEIGHT LOSS/5-10 KG 5 – 20 (DECLINES BP)

DIETS (DASH) 8 – 14

Sodium Restriction 2– 8

Physical Exercise 4– 9

Limit Alcohol Intake 2– 4

Smoking Cessation
JNC VIII Guideline. 2014
HIPERTENSI
TREATMENT
SELECTED INDICATIONS AND CONSIDERATIONS IN THE CHOICE OF
ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CKD

Ku, E, et al. Hypertension in CKD: Curriculum 2019.


American Journal of Kidney
HIPERTENSI
TREATMENT
SELECTED INDICATIONS AND CONSIDERATIONS IN THE CHOICE OF
ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CKD

Ku, E, et al. Hypertension in CKD: Curriculum 2019.


American Journal of Kidney
HIPERTENSI
TREATMENT

SELECTED INDICATIONS AND CONSIDERATIONS IN THE CHOICE


OF ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CKD

Ku, E, et al. Hypertension in CKD: Curriculum 2019.


American Journal of Kidney
HIPERTENSI
TREATMENT
2018 ESC/ECH HYPERTENSION GUIDELINES
ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CKD

Evaluate Potassium levels &


Ur/Creatinin serum

2018 ESC/ECH Hypertension Guidelines


HIPERTENSI
TREATMENT
2018 ESC/ECH HYPERTENSION GUIDELINES
ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CKD

2018 ESC/ECH Hypertension Guidelines


HIPERTENSI

JNC VIII Guideline. 2014


HIPERTENSI
TREATMENT
SPECIAL CASES & CONSIDERATIONS
Older Patients (Geriatric)
• JNC VIII  Target <150/90
• SPRINT (Systolic Blood Pressure Intervention Trial-USA) - 2017
Target  130/80 (>65 tahun)
CV Benefits in tighter BP Control
• Current ACC/AHA Guidelines
NOTE  Individualization of BP Targets : comorbid,
life expectancy, cognitive, QOL
JNC VIII Guidelines, ACC/AHA Guidelines on Hypertension
Ku, E, et al. Hypertension in CKD: Curriculum 2019.
HIPERTENSI
TREATMENT
SPECIAL CASES & CONSIDERATIONS
Women and Pregnancy
• Avoid ACE-I or ARB
 Teratogenic Effect (esp 1st Trimester)
• Use Ca Antagonist + B-blocker
Nifedipine, Labetalol, Methyldopa
• Diuretics may increase Risk of Olygohydramnions

JNC VIII Guidelines, ACC/AHA Guidelines on Hypertension


Ku, E, et al. Hypertension in CKD: Curriculum 2019.
HIPERTENSI
TREATMENT
SPECIAL CASES & CONSIDERATIONS

CKD post Kidney Transplant

• KDIGO + ACC/AHA  Target <130/90


• No Specific 1st line drug of choice.

JNC VIII Guidelines, ACC/AHA Guidelines on Hypertension


Ku, E, et al. Hypertension in CKD: Curriculum 2019.
HIPERTENSI
TREATMENT SUMMARY
2018 ESC/ECH HYPERTENSION GUIDELINES
ANTIHYPERTENSIVE AGENTS FOR PATIENTS WITH CKD

2018 ESC/ECH Hypertension Guidelines

You might also like